SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 8-K: (Original Filing)
[SKYSTAR COMMENCES TESTING ON TWO ADDITIONAL NEW PRODUCT DOSAGE FORMS TO FURTHER EXPAND THE COMPANY’S PRODUCT LINES The new dosage forms projected to generate $5 million in additional revenue by fiscal 2011 XI'AN, CHINA – May 12, 2010 - Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) ("Skystar" or the "Company"), The product testing process will ensure that the new dosage forms will adhere]